女，汉族，中共党员，医学博士，西北大学生命科学与医学部副教授，硕士研究生导师。主要从事慢性肾脏病发病机制及中药防治机制研究。主要研究方向：1）肾间质纤维化发病机制；2）糖尿病肾病蛋白尿发病机制；3）中药活性成分防治慢性肾脏病机制；4）慢性肾脏病生物标志物发现。在慢性肾脏病的发病机制、治疗靶点、早期生物标志物鉴定以及中药活性成分的肾保护机制方面取得了一系列创新性成果，入选中国科协青年人才托举工程项目；入选陕西省高层次人才引进计划；入选2023年和2022年全球高被引学者；入选2023年全球前2%顶尖科学家；共发表SCI论文50余篇，H-index为35，以第一作者（第一位）和通讯作者在Nature Communications（IF=16.6）、Trends in Pharmacological Sciences（IF=13.8）、Medicinal Research Reviews（IF= 13.3）、Redox Biology（IF=11.4）等发表SCI论文20篇，其中中科院大类一区TOP期刊论文9篇；IF>10.0的4篇；总被引次超过4200次，同时入选ESI热点论文和高被引论文4篇，ESI高被引论文1篇。主持国家自然科学基金委青年项目等科研项目。现担任中国中药协会肾病中药发展研究专业委员会青委秘书长、中华中医药学会肾病分会青年委员、中国中西医结合学会内分泌分会青年委员，兼职SCI杂志Frontiers in Pharmacology特邀副主编、Metabolites特邀编辑。参与2022年北京市科学技术进步奖二等奖和2021年中华中医药学会科学技术奖一等奖各1项。

教育及工作经历:

2011.09-2015.07，西北大学生命科学学院，本科，中药学，导师：赵英永教授

2015.09-2020.07，西北大学生命科学学院，博士，中药学，导师：赵英永教授

2020.07-2023.03，中日友好医院临床医学研究所，博士后，导师：李平教授、张国强教授

2023.06至今，西北大学生命科学学院，副教授

社会兼职

中国中药协会肾病中药发展研究专业委员会青委秘书长

中华中医药学会肾病分会青年委员

中国中西医结合学会内分泌分会青年委员

SCI杂志Frontiers in Pharmacology特邀副主编

SCI杂志Metabolites特邀编辑

SCI杂志Biomed Research International学术编辑

获奖

个人荣誉

1.     2023年，入选中国科协青年人才托举工程项目（中国科学技术协会）

2.     2023年，入选陕西省高层次人才引进计划

3.     2023年，入选全球前2%顶尖科学家（Elsevier与美国斯坦福大学）

4.     2023年，入选全球高被引学者（科睿唯安Clarivate）

5.     2022年，入选全球高被引学者（科睿唯安Clarivate）

6.     2022年，获陕西省优秀博士学位论文（陕西省学位委员会）

7.     2021年，入选北京市科学技术协会青年人才托举工程项目（北京市科学技术协会）

8.     2018年，获教育部首届全国高校“百名研究生党员标兵”称号（教育部）

成果奖

1.     2022年，从肝脾肾论治慢性肾脏病基础研究与临床应用，北京市科学技术进步奖二等奖；6/10

2.     2021年，基于“五脏相关”理论的中医药治疗慢性肾脏病基础研究与临床应用，中华中医药学会科学技术奖一等奖，7/15

3.     2017年，利水渗湿中药肾保护的药效物质基础，陕西高等学校科学技术奖一等奖，4/7

承担的科研项目

1.       茯苓酸A作用于Sirt3调控β-catenin去乙酰化抗肾间质纤维化的机制研究(82104511)，国家自然科学基金青年项目，2022.01-2024.12，在研，主持

2.       中国科协青年人才托举工程项目，中国科学技术协会，2023.10-2026.05，在研，主持

3.       茯苓酸A作用于NEDP1抑制PKM2拟素化改善DKD糖酵解异常的机制研究(2024JC-YBQN-0875)，陕西省自然科学基础研究计划一般项目（青年），2024.01-2025.12，在研，主持

4.       北京市科学技术协会青年人才托举工程项目(BYESS2022029)，北京市科学技术协会，2022.01-2024.12，在研，主持

5.       基于Sirt3介导的β-catenin去乙酰化探讨茯苓酸A抗肾间质纤维化的机制(2021M639579)，中国博士后科学基金面上资助，2021.06-2023.03，结题，主持

6.       升清降浊法通过调节肠道菌群失调治疗DKD及抗肾纤维化的作用机制研究(U23A20504)，国家自然科学基金区域创新发展联合基金重点项目，2024.01-2027.12，在研，参与

7.       中药毒性理论与安全用药传承创新团队(ZYYCXTD-202005)，国家中医药管理局国家中医药传承创新团队项目，2021.01-2023.12，结题，参与

8.       糖肾方改善宿主和肠源性代谢产物紊乱而发挥DKD肝肾同治的作用机制研究(82174296)，国家自然科学基金-面上项目，2022.01-2025.12，在研，参与

9.       基于组蛋白去甲基化酶JMJD3调控的脂质自噬研究糖肾方减轻糖尿病肾损伤的作用机制(82174144)，国家自然科学基金-面上项目，2022.01-2025.12，在研，参与

10.    E4BP4通过促进白色脂肪组织分解升高2型糖尿病空腹血糖的机制研究(82170817)，国家自然科学基金-面上项目，2022.01-2025.12，在研，参与

学术会议报告

1.       基于代谢组学鉴定慢性肾脏病的生物标志物及干预新靶点，第十六次全国中西医结合内分泌代谢病学术大会，2023.9.22，哈尔滨

2.       茯苓酸A作用于Sirt3介导β-catenin去乙酰化抗肾间质纤维化的机制研究，第七届肾病中药发展研究学术大会，2023.4.14，武汉

3.       慢性肾脏病新靶点及茯苓酸的干预机制，中华中医药学会肾病分会2022年学术会议，2022.12.23，厦门

4.       Sirt3在急慢性器官损伤中的保护机制，北京中医药大学中医内科学教育部重点实验室成立二十周年纪念学术活动，2022.12.6，北京

5.       基于代谢组学技术鉴定慢性肾脏病的生物标志物及药物干预靶点，中国中药协会第五届肾病中药发展研究大会，2020.7.24，北京

6.       Sirt3改善脓毒症诱导肺损伤的机制研究，2021年首都急危重症医学高峰论坛，2021.11.28，北京

7.       年青人的科研之路，2020年京津冀急诊急救联盟峰会，2020.12.05，北京

主要研究成果

第一作者或通讯作者文章（2023年影响因子）：

1.       Dan-Qian Chen^#, Gang Cao^#, Hua Chen^#, Christos P. Argyopoulos, Hui Yu, Wei Su, Lin Chen, David C. Samuels, Shougang Zhuang, George P. Bayliss, Shilin Zhao, Xiao-Yong Yu, Nosratola D. Vaziri, Ming Wang, Dan Liu, Jia-Rong Mao, Shi-Xing Ma, Jin Zhao, Yuan Zhang, You-Quan Shang, Huining Kang, Fei Ye, Xiao-Hong Cheng, Xiang-Ri Li, Li Zhang, Mei-Xia Meng, Yan Guo*, Ying-Yong Zhao*. Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan. Nature Communications 2019; 10: 1476. [IF=16.6] (中科院大类一区TOP期刊，ESI热点论文和ESI高被引论文)

2.       Dan-Qian Chen, Ya-Long Feng, Gang Cao, Ying-Yong Zhao*. Natural products as a source for antifibrosis therapy. Trends in Pharmacological Sciences 2018; 39(11): 937-952. [IF=13.8] (中科院大类一区TOP期刊，ESI热点论文和ESI高被引论文)

3.       Dan-Qian Chen*, Yan Guo, Li Xin, Guo-Qiang Zhang*, Ping Li*. Small molecules as modulators of regulated cell death against ischemia/reperfusion injury. Medicinal Research Reviews 2022; 42(6):2067-2101. [IF=13.3] (中科院大类一区TOP期刊)

4.       Dan-Qian Chen^#, Gang Cao^#, Hua Chen, Dan Liu, Wei Su, Xiao-Yong Yu, Nosratola D. Vaziri, Xiu-Hua Liu, Xu Bai, Li Zhang, Ying-Yong Zhao*. Gene and protein expressions and metabolomics exhibit activated redox signaling and wnt/β-catenin pathway are associated with metabolite dysfunction in patients with chronic kidney disease. Redox Biology 2017; 12: 505-521. [IF=11.4] (中科院大类一区TOP期刊，ESI热点论文和ESI高被引论文)

5.       Dan-Qian Chen*, Lin Chen, Yan Guo, Xia-Qing Wu, Ting-Ting Zhao, Hai-Ling Zhao, Hao-Jun Zhang, Mei-Hua Yan, Guo-Qiang Zhang, Ping Li*. Poricoic acid A suppresses renal fibroblast activation and interstitial fibrosis in UUO rats via up-regulating Sirt3 and promoting β-catenin K49 deacetylation. Acta Pharmacologica Sinica 2023; 44(5):1038-1050. [IF=8.2] (中科院大类一区TOP期刊)

6.       Dan-Qian Chen, Yan-Ni Wang, Nosratola D. Vaziri, Lin Chen, He-He Hu, Ying-Yong Zhao*. Poricoic acid A activates AMPK to attenuate fibroblast activation and abnormal extracellular matrix remodelling in renal fibrosis. Phytomedicine 2020; 72: 153232. [IF=7.9] (中科院大类一区TOP期刊)

7.       Dan-Qian Chen, He-He Hu, Yan-Ni Wang, Ya-Long Feng, Gang Cao, Ying-Yong Zhao*. Natural products for the prevention and treatment of kidney disease. Phytomedicine 2018; 50: 50-60. [IF=7.9] (中科院大类一区TOP期刊)

8.       Dan-Qian Chen^#, Ya-Long Feng^#, Lin Chen, Jing-Ru Liu, Ming Wang, Nosratola D. Vaziri, Ying-Yong Zhao*. Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/Axl-NF-κB/Nrf2 axis. Free Radical Biology and Medicine 2019; 134: 484-497. [IF=7.4] (中科院大类一区TOP期刊，ESI高被引论文)

9.       Dan-Qian Chen^#, Hua Chen^#, Lin Chen, Nosratola D. Vaziri, Ming Wang, Xiang-Ri Li, Ying-Yong Zhao*. The link between phenotype and fatty acid metabolism in advanced chronic kidney disease. Nephrology Dialysis Transplantation 2017; 32(7): 1154–1166. [IF=6.1] (中科院大类一区TOP期刊，ESI热点论文和ESI高被引论文)

10.    Dan-Qian Chen*, Jun Wu, Ping Li*. Therapeutic mechanism and clinical application of Chinese herbal medicine against diabetic kidney disease. Frontiers in Pharmacology 2022; 13:1055296. [IF=5.6] (中科院大类二区TOP期刊)

11.    Dan-Qian Chen*, Yan Guo, Zhi-Yong Guo, Yu-Ping Tang*. Editorial: New insights into renal fibrosis and therapeutic effects of natural products volume II. Frontiers in Pharmacology 2022; 13:1053408. [IF=5.6] (中科院大类二区TOP期刊)

12.    Peng Liu^#, Jing Zhang^#, Yun Wang, Chen Wang, Xinping Qiu, Dan-Qian Chen*. Natural products against renal fibrosis via modulation of SUMOylation. Frontiers in Pharmacology 2022; 13: 800810. [IF=5.6] (中科院大类二区TOP期刊)

13.    Dan-Qian Chen^#, Hao-Jun Zhang^#, Wen Zhang, Kai Feng, Hui Liu, Hai-Ling Zhao, Ping Li^*. Tangshen Formula alleviates inflammatory injury against aged diabetic kidney disease through modulating gut microbiota composition and related amino acid metabolism. Experimental Gerontology 2024; Accepted. [IF=3.9] (中科院大类三区期刊)

14.    Dan-Qian Chen*, Mei-Jia Shen, Hui Wang, Yan Li, A-Ling Tang, Shan Li, Meng-Chen Xiong, Yan Guo, Guo-Qiang Zhang*. Sirt3 maintains microvascular endothelial adherens junction integrity to alleviate sepsis-induced lung inflammation by modulating the interaction of VE-cadherin and β-catenin. Oxidative Medicine and Cellular Longevity 2021; 2021: 8978795. [IF=6.874] (二区期刊)

15.    Peng Liu^#, Jing Zhang^#, Yun Wang, Zhengri Shen, Chen Wang, Dan-Qian Chen*, Xinping Qiu*. The active compounds and therapeutic target of Tripterygium wilfordii Hook. f. in attenuating proteinuria in diabetic nephropathy: A review. Frontiers in Medicine 2021; 8: 747922. [IF=3.9] (中科院大类三区期刊)

16.    Dan-Qian Chen^#, Xia-Qing Wu^#, Lin Chen, He-He Hu, Yan-Ni Wang, Ying-Yong Zhao*. Poricoic acid A as a modulator of TPH-1 expression inhibits renal fibrosis via modulating protein stability of β-catenin and β-catenin-mediated transcription. Therapeutic Advances in Chronic Disease 2020; 11: 2040622320962648. [IF=3.5] (中科院大类三区期刊)

17.    Dan-Qian Chen, Gang Cao, Hui Zhao, Lin Chen, Tian Yang, Ming Wang, Nosratola D. Vaziri, Yan Guo, Ying-Yong Zhao*. Combined melatonin and poricoic acid A inhibits renal fibrosis through modulating the interaction of Smad3 and β-catenin pathway in AKI-to-CKD continuum. Therapeutic Advances in Chronic Disease 2019; 10: 2040622319869116. [IF=3.5] (中科院大类三区期刊)

18.    Dan-Qian Chen, Hua Chen, Lin Chen, Dan-Dan Tang, Hua Miao, Ying-Yong Zhao*. Metabolomic application in toxicity evaluation and toxicological biomarker identification of natural product. Chemico-Biological Interactions 2016; 252: 114-130. [IF=5.1] (中科院大类二区期刊)

19.    Dan-Qian Chen^#, Ya-Long Feng^#, Ting Tian, Hua Chen, Lu Yin, Ying-Yong Zhao*, Rui-Chao Lin. Diuretic and anti-diuretic activities of fractions of Alismatis Rhizoma. Journal of Ethnopharmacology 2014; 157: 114–118. [IF=5.4] (中科院大类二区TOP期刊)

20.    Dan-Qian Chen^#, Jun-Min An^#, Ya-Long Feng, Ting Tian, Xiang-Yang Qin, Ying-Yong Zhao*. Cloud-point extraction combined with liquid chromatography for determination of ergosterol, a natural product with diuretic activity, in rat plasma, urine and faeces. Journal of Analytical Methods in Chemistry 2013; 2013: 479056. [IF=2.6] (中科院大类四区期刊)

参与发表论文（2023年影响因子）：

21.    Ya-Long Feng^#, Gang Cao^#, Dan-Qian Chen^#, Nosratola D. Vaziri, Lin Chen, Jun Zhang, Ming Wang, Yan Guo, Ying-Yong Zhao*. Microbiome-metabolomics reveals gut microbiota associated with glycine-conjugated metabolites and polyamine metabolism in chronic kidney disease. Cellular and Molecular Life Sciences 2019; 76(24): 4961-4978. [IF=8.0]

22.    Ming Wang^#, Dan-Qian Chen^#, Lin Chen, Gang Cao, Hui Zhao, Dan Liu, Nosratola D. Vaziri, Yan Guo, Ying-Yong Zhao*. Novel inhibitors of the cellular RAS components, Poricoic acids, target Smad3 phosphorylation and Wnt/β-catenin pathway against renal fibrosis. British Journal of Pharmacology 2018; 175(13) :2689-2708. [IF=7.3] (TOP期刊，ESI高被引论文)

23.    Lin Chen^#, Dan-Qian Chen^#, Jing-Ru Liu, Jun Zhang, Nosratola D. Vaziri, Shougang Zhuang, Hua Chen, Ya-Long Feng, Yan Guo, Ying-Yong Zhao*. Unilateral ureteral obstruction causes gut microbial dysbiosis and metabolome disorders contributing to tubulointerstitial fibrosis. Experimental & Molecular Medicine 2019; 51 :38. [IF=12.8]

24.    Ming Wang^#, Dan-Qian Chen^#, Lin Chen, Dan Liu, Hui Zhao, Zhi-Hao Zhang, Nosratola D. Vaziri, Yan Guo, Ying-Yong Zhao*, Gang Cao. Novel RAS inhibitors poricoic acid ZG and poricoic acid ZH attenuate renal fibrosis via Wnt/β-catenin pathway and targeted phosphorylation smad3 signaling. Journal of Agricultural and Food Chemistry 2018; 66(8): 1828-1842. [IF=6.1] (一区TOP期刊，ESI热点论文和ESI高被引论文)

25.    Ming Wang^#, Dan-Qian Chen^#, Min-Chang Wang, Hua Chen, Lin Chen, Dan Liu, Hui Zhao, Ying-Yong Zhao*. Poricoic acid ZA, a novel RAS inhibitor, attenuates tubulo-interstitial fibrosis and podocyte injury by inhibiting TGF-β/Smad signaling pathway. Phytomedicine 2017; 36: 243-253. [IF=7.9] (TOP期刊)

26.    Lin Chen^#, Dan-Qian Chen^#, Ming Wang, Dan Liu, Hua Chen, Fang Dou, Nosratola D. Vaziri, Ying-Yong Zhao*. Role of RAS/Wnt/β-catenin axis activation in the pathogenesis of podocyte injury and tubulo-interstitial nephropathy. Chemico-Biological Interactions 2017; 273: 56-72. [IF=5.1] (ESI高被引论文)

27.    Ya-Long Feng, Dan-Qian Chen, Nosratola D. Vaziri, Yan Guo, Ying-Yong Zhao*. Small molecule inhibitors of epithelial-mesenchymal transition for the treatment of cancer and fibrosis. Medicinal Research Reviews 2020; 40(1): 54-78. [IF=13.3] (一区TOP期刊)

28.    Jie Ping, Olufunmilola Oyebamiji, Hui Yu, Scott Ness, Jeremy Chien, Fei Ye, Huining Kang, David Samuels, Sergey Ivanov, Danqian Chen, Ying-Yong Zhao, Yan Guo*. MutEx: a multifaceted gateway for exploring integrative pan-cancer genomic data. Briefings in Bioinformatics 2020; 21(4): 1479-1486. [IF=9.5]

29.    Hua Miao, Gang Cao, Xia-Qing Wu, Yuan-Yuan Chen, Dan-Qian Chen, Lin Chen, Nosratola D. Vaziri, Ya-Long Feng, Wei Su, Yi Gao, Shougang Zhuang, Xiao-Yong Yu, Li Zhang, Yan Guo, Ying-Yong Zhao*. Identification of endogenous 1-aminopyrene as a novel mediator of progressive chronic kidney disease via aryl hydrocarbon receptor activation. British Journal of Pharmacology 2020; 177(15): 3415-3435. [IF=7.3] (TOP期刊)

30.    Quanhu Sheng, Hui Yu, Olufunmilola Oyebamiji, Jiandong Wang, Danqian Chen, Scott Ness, Ying-Yong Zhao, Yan Guo*. AnnoGen: annotating genome-wide pragmatic features. Bioinformatics 2020; 36(9): 2899-2901. [IF=5.8]

31.    Lin Chen, Tian Yang, De-Wen Lu, Hui Zhao, Ya-Long Feng, Hua Chen, Dan-Qian Chen, Nosratola D. Vaziri, Ying-Yong Zhao*. Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment. Biomedicine & Pharmacotherapy 2018; 101: 670–681. [IF=7.5] (ESI热点论文和ESI高被引论文)

32.    Ya-Long Feng^#, Hua Chen^#, Dan-Qian Chen, Nosratola D. Vaziri, Wei Su, Shi-Xing Ma, You-Quan Shang, Jia-Rong Mao, Xiao-Yong Yu, Li Zhang, Yan Guo, Ying-Yong Zhao*. Activated NF-κB/Nrf2 and Wnt/β-catenin pathways are associated with lipid metabolism in CKD patients with microalbuminuria and macroalbuminuria. Biochimica et Biophysica Acta-Molecular Basis of Disease 2019; 1865(9): 2317-2332. [IF=6.2] (TOP期刊)

33.    Hua Chen, Tian Yang, Min-Chang Wang, Dan-Qian Chen, Yang Yang*, Ying-Yong Zhao*. Novel RAS inhibitor 25-O-methylalisol F attenuates epithelial-to-mesenchymal transition and tubulo-interstitial fibrosis by selectively inhibiting TGF-β-mediated Smad3 phosphorylation. Phytomedicine 2018; 42: 207-218. [IF=7.9] (TOP期刊，ESI高被引论文)

34.    Lin Chen, Gang Cao, Ming Wang, Ya-Long Feng, Dan-Qian Chen, Nosratola D. Vaziri, Shougang Zhuang, Ying-Yong Zhao*. The matrix metalloproteinase-13 inhibitor poricoic acid ZI ameliorates renal fibrosis by mitigating epithelial-mesenchymal transition. Molecular Nutrition & Food Research 2019; 63(13): 1900132. [IF=5.2] (TOP期刊，ESI热点论文和ESI高被引论文)

35.    Zhi-Hao Zhang, Ming-Hua Li, Dan Liu, Hua Chen, Dan-Qian Chen, Ning-Hua Tan, Shuang-Cheng Ma*, Ying-Yong Zhao*. Rhubarb protect against tubulointerstitial fibrosis by inhibiting TGF-β/Smad pathway and improving abnormal metabolome in chronic kidney disease. Frontiers in Pharmacology 2018; 9: 1029. [IF=5.6]

36.    Lin Chen, Wei Su, Hua Chen, Dan-Qian Chen, Ming Wang, Yan Guo, Ying-Yong Zhao*. Proteomics for biomarker identification and clinical application in kidney disease. Advances in Clinical Chemistry 2018; 85: 91-113. [IF=6.0] (ESI高被引论文)

37.    He-He Hu, Dan-Qian Chen, Yan-Ni Wang, Ya-Long Feng, Gang Cao, Nosratola D. Vaziri, Ying-Yong Zhao*. New insights into TGF-β/Smad signaling in tissue fibrosis. Chemico-Biological Interactions 2018; 292: 76-83. [IF=5.1] (ESI热点论文和ESI高被引论文)

38.    Hua Chen, Lin Chen, Dan Liu, Dan-Qian Chen, Nosratola D. Vaziri, Xiao-Yong Yu, Li Zhang, Wei Su, Xu Bai, Ying-Yong Zhao*. Combined clinical phenotype and lipidomic analysis reveals the impact of chronic kidney disease on lipid metabolism. Journal of Proteome Research 2017; 16(4): 1566-1578. [IF=4.4] (ESI高被引论文)

39.    Ya-Long Feng, Ping Lei, Hua Chen, Ting Tian, Lu Yin, Dan-Qian Chen, Qibing Mei, Ying-Yong Zhao*, Rui-Chao Lin. Diuretic activity of some fractions of the epidermis of Poria cocos. Journal of Ethnopharmacology 2013; 150(3): 1114-1118. [IF=5.4]

40.    Ya-Long Feng, Hua Chen, Ting Tian, Dan-Qian Chen, Ying-Yong Zhao*, Rui-Chao Lin. Diuretic and anti-diuretic activities of the ethanol and aqueous extracts of Alismatis Rhizoma. Journal of Ethnopharmacology 2014; 154(2):386-390. [IF=5.4]

41.    Fengyao Yan, Dan-Qian Chen, Jijun Tang, Ying-Yong Zhao, Yan Guo. Serum metabolites associated with blood pressure in chronic kidney disease patients. Metabolites 2022; 12(4):281. [IF=4.1]

42.    Yan Guo*, Hui Yu, Danqian Chen, Ying-Yong Zhao. Machine learning distilled metabolite biomarkers for early stage renal injury. Metabolomics 2019; 16(1):4. [IF=3.6]

43.    Ying-Yong Zhao*, Ping Lei, Dan-Qian Chen, Ya-Long Feng, Xu Bai. Renal metabolic profiling of early renal injury and renoprotective effects of poria cocos epidermis using UPLC Q-TOF/HSMS/MSE. Journal of Pharmaceutical and Biomedical Analysis 2013; 81-82(1):202-209. [IF=3.4]

44.    Ying-Yong Zhao*, Li Zhang, Ya-Long Feng, Dan-Qian Chen, Zhi-Hui Xi, Xiao Du, Xu Bai, Rui-Chao Lin. Pharmacokinetics of 2,3,5,4’-tetrahydroxystilbene-2-O-β-D-glucoside in rat using ultra-performance LC-quadrupole TOF-MS. Journal of Separation Science 2013; 36(5): 863-871. [IF=3.1]

45.    Zhi-Hao Zhang, Jia-Rong Mao, Hua Chen, Wei Su, Yuan Zhang, Li Zhang, Dan-Qian Chen, Ying-Yong Zhao*, Nosratola D. Vaziri. Removal of uremic retention products by hemodialysis is coupled with indiscriminate loss of vital metabolites. Clinical Biochemistry 2017; 50(18): 1078-1086. [IF=2.8]

46.    Ying-Yong Zhao*, Hua Chen, Ting Tian, Dan-Qian Chen, Xu Bai, Feng Wei. A pharmaco-metabonomic study on chronic kidney disease and therapeutic effect of ergone by UPLC-QTOF/HDMS. Plos One 2014; 9(12): e115467. [IF=3.7]

47.    Hui Yu, Danqian Chen, Olufunmilola Oyebamiji, Ying-Yong Zhao, Yan Guo*. Expression correlation attenuates within and between key signaling pathways in chronic kidney disease. BMC Medical Genomics 2020; 13(Suppl 9):134. [IF=2.7]

48.    Hua Miao, Li Zhang, Dan-Qian Chen, Hua Chen, Ying-Yong Zhao*, Shuang-Cheng Ma*. Urinary biomarker and treatment mechanism of Rhizoma Alismatis on hyperlipidemia. Biomedical Chromatography 2017; 31(4): e3829. [IF=1.8]